BR112017012706A2 - formulações de sunitinibe e métodos para uso destas no tratamento de transtornos oculares - Google Patents

formulações de sunitinibe e métodos para uso destas no tratamento de transtornos oculares

Info

Publication number
BR112017012706A2
BR112017012706A2 BR112017012706-7A BR112017012706A BR112017012706A2 BR 112017012706 A2 BR112017012706 A2 BR 112017012706A2 BR 112017012706 A BR112017012706 A BR 112017012706A BR 112017012706 A2 BR112017012706 A2 BR 112017012706A2
Authority
BR
Brazil
Prior art keywords
sunitinib
methods
analog
treatment
prevent
Prior art date
Application number
BR112017012706-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Fu Jie
Hanes Justin
Kays Joshua
Yu Yun
Yang Ming
Cleland Jeffrey
J. Stark Walter
Xu Qingguo
Yang Jin
Original Assignee
The Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55069169&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017012706(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Johns Hopkins University filed Critical The Johns Hopkins University
Publication of BR112017012706A2 publication Critical patent/BR112017012706A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
BR112017012706-7A 2014-12-15 2015-12-15 formulações de sunitinibe e métodos para uso destas no tratamento de transtornos oculares BR112017012706A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462092118P 2014-12-15 2014-12-15
US62/092,118 2014-12-15
US201562139306P 2015-03-27 2015-03-27
US62/139,306 2015-03-27
PCT/US2015/065894 WO2016100392A1 (en) 2014-12-15 2015-12-15 Sunitinib formulations and methods for use thereof in treatment of ocular disorders

Publications (1)

Publication Number Publication Date
BR112017012706A2 true BR112017012706A2 (pt) 2018-03-13

Family

ID=55069169

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017012706-7A BR112017012706A2 (pt) 2014-12-15 2015-12-15 formulações de sunitinibe e métodos para uso destas no tratamento de transtornos oculares

Country Status (19)

Country Link
US (4) US10525034B2 (enExample)
EP (3) EP3233058A1 (enExample)
JP (3) JP6847848B2 (enExample)
KR (2) KR20170094793A (enExample)
CN (3) CN117398350A (enExample)
AU (2) AU2015362621B2 (enExample)
BR (1) BR112017012706A2 (enExample)
CA (1) CA2972075C (enExample)
CO (1) CO2017007003A2 (enExample)
EA (1) EA201791337A1 (enExample)
HK (1) HK1243942A1 (enExample)
IL (1) IL252943A0 (enExample)
MX (1) MX2017007873A (enExample)
NZ (1) NZ733130A (enExample)
PH (1) PH12017501097A1 (enExample)
RU (1) RU2729731C2 (enExample)
SG (2) SG10201903210WA (enExample)
WO (2) WO2016100392A1 (enExample)
ZA (1) ZA201703875B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011106702A2 (en) 2010-02-25 2011-09-01 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
US11180760B2 (en) * 2012-03-09 2021-11-23 The Johns Hopkins University Identification of molecular pathways and methods of use thereof for treating retinal neurodegeneration and other neurodegenerative disorders
EP3233058A1 (en) * 2014-12-15 2017-10-25 The Johns Hopkins University Sunitinib formulations and methods for use thereof in treatment of glaucoma
EA037327B1 (ru) 2015-09-22 2021-03-12 Грейбуг Вижн, Инк. Соединения и композиции для лечения глазных расстройств
CN108367079B (zh) 2015-11-12 2022-11-22 灰色视觉公司 用于治疗的聚集性微粒
CN110662543A (zh) 2017-03-23 2020-01-07 灰色视觉公司 用于治疗眼部疾病的药物和组合物
WO2018182527A1 (en) * 2017-03-30 2018-10-04 National University Of Singapore Method for treating inflammatory complications in eye diseases
EP3621654A4 (en) 2017-05-10 2021-02-17 Graybug Vision, Inc. PROLONGED-RELEASE MICROPARTICLES AND SUSPENSIONS OF THESE INTENDED FOR MEDICAL THERAPY
US20200206137A1 (en) * 2017-07-17 2020-07-02 Wolfcreek Biotech Pte Ltd Microparticle formulations for delivery of active agents
JP2021529747A (ja) * 2018-06-25 2021-11-04 タイタン ファーマシューティカルズ インコーポレイテッド 親油性又は両親媒性医薬物質の放出のためのインプラント
WO2020039264A2 (en) * 2018-08-18 2020-02-27 Ftf Pharma Private Limited Chemotherapeutic pharmaceutical suspension for oral dosage
CN110946858A (zh) * 2018-09-27 2020-04-03 中国科学院上海生命科学研究院 吲哚满酮衍生物在治疗肥胖及其相关疾病中的应用
TW202035364A (zh) * 2018-09-27 2020-10-01 美商灰色視覺公司 用於眼部遞送之化合物及組合物
KR102308227B1 (ko) * 2018-10-31 2021-10-05 주식회사 삼양홀딩스 수니티닙을 함유하는 경구용 정제 조성물
KR102322429B1 (ko) * 2018-10-31 2021-11-08 주식회사 삼양홀딩스 수니티닙을 함유하는 경구용 제제 및 그의 제조 방법
TW202031292A (zh) * 2018-11-15 2020-09-01 美商灰色視覺公司 改良的聚集微粒
KR102442103B1 (ko) * 2019-04-30 2022-09-08 주식회사 엘지화학 캐스파제 저해제의 프로드럭
US11471412B1 (en) * 2019-05-10 2022-10-18 University Of South Florida Nanoparticles and nanogel drug compositions for treatment of age-related macular degeneration
CN110833425B (zh) * 2019-11-27 2022-12-30 佛山科学技术学院 一种用于鸡胚采血的血管托持器
WO2021113651A2 (en) * 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery
JP7759322B2 (ja) * 2019-12-04 2025-10-23 アシュバッタ セラピューティクス， インコーポレイテッド 眼に薬物送達するためのデンドリマー組成物および方法
KR20240025990A (ko) * 2022-08-19 2024-02-27 주식회사 스카이테라퓨틱스 무정형 수니티닙, 그 제조방법 및 이를 포함한 의약 조성물
KR20240028815A (ko) 2022-08-25 2024-03-05 주식회사 스카이테라퓨틱스 약리 활성 물질의 신규 분자회합체 및 이를 포함하는 약학 조성물
EP4611814A1 (en) 2022-11-04 2025-09-10 Semmelweis Egyetem In vivo targeting of therapeutic molecules to the retina via the optical system of the eye

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB929401A (en) 1958-12-22 1963-06-19 Upjohn Co Encapsulated emulsions and processes for their preparation
GB929406A (en) 1958-12-22 1963-06-19 Upjohn Co A process for the production of encapsulated material
GB969808A (en) 1962-06-08 1964-09-16 Boots Pure Drug Co Ltd Anthelmintic compositions and compounds
IT1148784B (it) 1980-04-09 1986-12-03 Eurand Spa Procedimento per la preparazione di microcapsule in un veicolo liquido
US4794000A (en) 1987-01-08 1988-12-27 Synthetic Blood Corporation Coacervate-based oral delivery system for medically useful compositions
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4991920A (en) 1988-12-27 1991-02-12 Andrzej Peczalski Optical converter
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US5441722A (en) 1994-02-18 1995-08-15 Merck & Co., Inc. Short synthesis of 5,6-dihydro-(S)-4-(ethylamino)-(S)-6-[C3 H3 ]-4[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide and related non radioactive compounds
GB9412273D0 (en) 1994-06-18 1994-08-10 Univ Nottingham Administration means
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
EP0805678B1 (en) 1995-01-05 2003-10-29 THE BOARD OF REGENTS acting for and on behalf of THE UNIVERSITY OF MICHIGAN Surface-modified nanoparticles and method of making and using same
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6841617B2 (en) 2000-09-28 2005-01-11 Battelle Memorial Institute Thermogelling biodegradable aqueous polymer solution
US6818018B1 (en) 1998-08-14 2004-11-16 Incept Llc In situ polymerizable hydrogels
US6632457B1 (en) 1998-08-14 2003-10-14 Incept Llc Composite hydrogel drug delivery systems
US6703047B2 (en) 2001-02-02 2004-03-09 Incept Llc Dehydrated hydrogel precursor-based, tissue adherent compositions and methods of use
AU2707500A (en) 1998-12-04 2000-06-26 Incept Llc Biocompatible crosslinked polymers
US20040258763A1 (en) 1999-02-03 2004-12-23 Bell Steve J.D. Methods of manufacture and use of calcium phosphate particles containing allergens
US6217895B1 (en) 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6287588B1 (en) 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
US6589549B2 (en) 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
CN101584867A (zh) 2000-10-31 2009-11-25 瑟莫迪克斯药品公司 提高生物活性分子传递的方法和组合物
GB0122318D0 (en) 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
US7060299B2 (en) 2002-12-31 2006-06-13 Battelle Memorial Institute Biodegradable microparticles that stabilize and control the release of proteins
WO2004084819A2 (en) * 2003-03-19 2004-10-07 University Of Kentucky Research Foundation Poly(acryloyl-hydroxyethyl starch)-plga composite microspheres
GB0307011D0 (en) 2003-03-27 2003-04-30 Regentec Ltd Porous matrix
CA2530136C (en) 2003-06-26 2012-10-16 Control Delivery Systems, Inc. In-situ gelling drug delivery system
US20090148527A1 (en) 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
US8957034B2 (en) 2004-01-28 2015-02-17 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
ES2246694B1 (es) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Nanoparticulas pegiladas.
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
EP1931387A4 (en) * 2005-09-07 2012-07-11 Southwest Res Inst BIODEGRADABLE MICROTEILED PHARMACEUTICAL FORMULATIONS WITH IMPROVED RELEASE RATES
US7501179B2 (en) 2005-12-21 2009-03-10 Boston Scientific Scimed, Inc. Block copolymer particles
US20070149593A1 (en) 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
CA2636716C (en) 2006-01-13 2014-12-23 Surmodics, Inc. Microparticle containing matrices for drug delivery
US20080166411A1 (en) 2006-04-10 2008-07-10 Pfizer Inc Injectable Depot Formulations And Methods For Providing Sustained Release Of Poorly Soluble Drugs Comprising Nanoparticles
ES2360538T3 (es) 2006-09-08 2011-06-06 Johns Hopkins University Composiciones para aumentar el transporte a través de moco.
GB0619869D0 (en) 2006-10-07 2006-11-15 Regentec Ltd Porous particles
ZA200902587B (en) 2006-11-09 2010-06-30 Alcon Res Ltd Water insoluble polymer matrix for drug delivery
GB0701896D0 (en) 2007-02-01 2007-03-14 Regentec Ltd Composition
JP2010519183A (ja) 2007-02-06 2010-06-03 インセプト エルエルシー 生理溶液の溶出のためのタンパク質の沈殿を用いる重合
US8492334B2 (en) 2007-06-21 2013-07-23 Yale University Sustained intraocular delivery of drugs from biodegradable polymeric microparticles
CN101081206A (zh) * 2007-06-29 2007-12-05 济南康泉医药科技有限公司 一种含酪氨酸激酶抑制剂的抗癌药物组合物
US9125807B2 (en) 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
AU2008315318B2 (en) 2007-10-26 2014-02-06 National Institute Of Immunology Biodegradable polymer scaffold and process for preparation thereof
US20090203709A1 (en) 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
EP2255788B1 (en) 2008-02-29 2015-07-22 Nagoya Industrial Science Research Institute Liposome for delivery to posterior segment of eye and pharmaceutical composition for disease in posterior segment of eye
CN101336890A (zh) 2008-05-30 2009-01-07 济南基福医药科技有限公司 一种抗癌缓释凝胶注射剂
US8993615B2 (en) * 2008-08-08 2015-03-31 The Johns Hopkins University Compositions and methods for treatment of neurodegenerative disease
TW201019963A (en) 2008-09-10 2010-06-01 Abbott Lab Polyethylene glycol lipid conjugates and uses thereof
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
JP2012515014A (ja) 2009-01-12 2012-07-05 ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッド 組織再生膜
CA3045436C (en) 2009-01-29 2025-10-07 Forsight Vision4 Inc Posterior segment drug delivery
US20120052041A1 (en) 2009-02-04 2012-03-01 The Brigham And Women's Hospital, Inc. Polymeric nanoparticles with enhanced drug-loading and methods of use thereof
EP2396070B1 (en) 2009-02-12 2024-12-04 Incept Llc Drug delivery through hydrogel plugs
ES2508290T3 (es) 2009-03-03 2014-10-16 Alcon Research, Ltd. Composición farmacéutica para la administracón de compuestos de inhibición del receptor de tirosina cinasa (RTKI) al ojo
GB0903810D0 (en) 2009-03-05 2009-04-22 Regentec Ltd Delivery system
WO2010114770A1 (en) 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
EP3960215B1 (en) 2009-12-15 2024-10-16 Incept, LLC Implants and biodegradable fiducial markers
WO2011106702A2 (en) * 2010-02-25 2011-09-01 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
US20130071349A1 (en) 2010-03-02 2013-03-21 Allergan, Inc. Biodegradable polymers for lowering intraocular pressure
US9162981B2 (en) 2010-03-23 2015-10-20 The Johns Hopkins University Compositions and methods for treatment of neurodegenerative disease
WO2011119995A2 (en) * 2010-03-26 2011-09-29 Cerulean Pharma Inc. Formulations and methods of use
WO2012039979A2 (en) 2010-09-10 2012-03-29 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
US8961501B2 (en) 2010-09-17 2015-02-24 Incept, Llc Method for applying flowable hydrogels to a cornea
CA2816977C (en) 2010-11-05 2019-10-29 The Johns Hopkins University Compositions and methods relating to reduced mucoadhesion
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
WO2012112674A2 (en) * 2011-02-15 2012-08-23 The Johns Hopkins University Compounds and methods of use thereof for treating neurodegenerative disorders
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
CN103127096B (zh) * 2011-12-02 2015-11-25 杨子娇 吡咯基取代的吲哚类化合物在治疗青光眼病的应用
EP3613413A1 (en) 2011-12-05 2020-02-26 Incept, LLC Medical organogel processes and compositions
AU2012351994B2 (en) 2011-12-14 2015-11-05 The Johns Hopkins University Nanoparticles with enhanced mucosal penetration or decreased inflammation
KR101811917B1 (ko) 2012-01-19 2017-12-22 더 존스 홉킨스 유니버시티 점액 침투 강화를 나타내는 나노 입자 제형
US8962577B2 (en) 2012-03-16 2015-02-24 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
EP2825207B1 (en) 2012-03-16 2020-08-19 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
US20140107025A1 (en) 2012-04-16 2014-04-17 Jade Therapeutics, Llc Ocular drug delivery system
US9056057B2 (en) 2012-05-03 2015-06-16 Kala Pharmaceuticals, Inc. Nanocrystals, compositions, and methods that aid particle transport in mucus
NZ741873A (en) 2012-05-03 2019-04-26 Kala Pharmaceuticals Inc Pharmaceutical nanoparticles showing improved mucosal transport
HK1208377A1 (en) 2012-05-04 2016-03-04 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
US9533068B2 (en) 2012-05-04 2017-01-03 The Johns Hopkins University Drug loaded microfiber sutures for ophthalmic application
WO2013177367A2 (en) * 2012-05-23 2013-11-28 The Johns Hopkins University Compounds and methods of use thereof for treating neurodegenerative disorders
JP2017512748A (ja) * 2012-06-25 2017-05-25 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ スニチニブを含んでいる眼科用局所医薬組成物
WO2014043625A1 (en) * 2012-09-17 2014-03-20 Bind Therapeutics, Inc. Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
CN103848985B (zh) * 2012-11-30 2018-03-02 杨子剑 含有舒尼替尼类似物结构的新化合物以及制备方法和用途
CN105188666A (zh) 2013-04-01 2015-12-23 阿勒根公司 用于持续的眼内释放的微球药物递送系统
CN104208715B (zh) 2013-05-31 2016-12-28 天津键凯科技有限公司 具有提高的药物生物活性的低分子量聚乙二醇药物结合物
US20160372268A1 (en) 2013-06-18 2016-12-22 Showa Denko K.K. Capacitor anode and production method for same
US10646027B2 (en) 2013-08-29 2020-05-12 Sayeeda Mazed Multifunctional personal care devices/apparatuses and compositions for hair or skin
CA2933900A1 (en) 2013-12-20 2015-06-25 Georgia Tech Research Corporation Formulations and methods for targeted ocular delivery of therapeutic agents
KR101564401B1 (ko) 2014-04-10 2015-11-02 한국화학연구원 브린졸아마이드의 제조방법
CA2957764C (en) 2014-08-13 2019-07-02 The Johns Hopkins University Glucocorticoid-loaded nanoparticles for prevention of corneal allograft rejection and neovascularization
WO2016060925A1 (en) 2014-10-16 2016-04-21 Incept, Llc Ocular gels or hydrogels and microinjectors
WO2016065245A1 (en) 2014-10-24 2016-04-28 Incept, Llc Extra luminal scaffold
EP3858329A1 (en) 2014-12-10 2021-08-04 Incept, LLC Hydrogel drug delivery implants
EP3233058A1 (en) * 2014-12-15 2017-10-25 The Johns Hopkins University Sunitinib formulations and methods for use thereof in treatment of glaucoma
JP6479485B2 (ja) 2015-01-15 2019-03-06 大内新興化学工業株式会社 眼疾患治療用ナノ粒子製剤
WO2016118506A1 (en) 2015-01-20 2016-07-28 The Johns Hopkins University Compositions for the sustained release of anti-glaucoma agents to control intraocular pressure
JP2018520093A (ja) 2015-05-05 2018-07-26 シヴィダ・ユーエス・インコーポレイテッドＰｓｉｖｉｄａ Ｕｓ， Ｉｎｃ． 注射可能なデポー製剤
EP4279064A3 (en) 2015-05-12 2024-02-28 Incept, LLC Drug delivery from hydrogels
WO2017015591A1 (en) 2015-07-22 2017-01-26 Incept, Llc Coated punctal plug
WO2017091749A1 (en) 2015-11-25 2017-06-01 Incept, Llc Shape changing drug delivery devices and methods

Also Published As

Publication number Publication date
AU2015362621B2 (en) 2019-01-17
US20170360750A1 (en) 2017-12-21
EP3233056B1 (en) 2023-11-15
US20170273901A1 (en) 2017-09-28
HK1243942A1 (zh) 2018-07-27
SG10201903210WA (en) 2019-05-30
PH12017501097A1 (en) 2017-11-27
RU2017123358A3 (enExample) 2019-08-30
KR20170094794A (ko) 2017-08-21
EP4445952A3 (en) 2025-01-15
WO2016100380A1 (en) 2016-06-23
ZA201703875B (en) 2019-11-27
JP2018500394A (ja) 2018-01-11
JP2021119183A (ja) 2021-08-12
IL252943A0 (en) 2017-08-31
NZ733130A (en) 2018-09-28
CO2017007003A2 (es) 2017-10-20
SG11201704869VA (en) 2017-07-28
MX2017007873A (es) 2017-11-06
AU2015362621A1 (en) 2017-07-13
JP6882186B2 (ja) 2021-06-02
WO2016100392A1 (en) 2016-06-23
RU2729731C2 (ru) 2020-08-11
RU2017123358A (ru) 2019-01-17
CA2972075C (en) 2020-07-14
AU2019202037A1 (en) 2019-04-18
AU2019202037B2 (en) 2021-01-21
CN107205940A (zh) 2017-09-26
US11013719B2 (en) 2021-05-25
JP2017537985A (ja) 2017-12-21
EP3233058A1 (en) 2017-10-25
CA2972075A1 (en) 2016-06-23
US20200147044A1 (en) 2020-05-14
US20210251959A1 (en) 2021-08-19
US10525034B2 (en) 2020-01-07
EP4445952A2 (en) 2024-10-16
EA201791337A1 (ru) 2017-11-30
CN107278151A (zh) 2017-10-20
KR20170094793A (ko) 2017-08-21
EP3233056A1 (en) 2017-10-25
JP6847848B2 (ja) 2021-03-24
CN117398350A (zh) 2024-01-16

Similar Documents

Publication Publication Date Title
BR112017012706A2 (pt) formulações de sunitinibe e métodos para uso destas no tratamento de transtornos oculares
CL2016001874A1 (es) Forma de dosificación oral sólida de liberación modificada que comprende pridopidina y un excipiente de control de velocidad; formulación farmacéutica que comprende a la forma de dosificación; uso de la forma de dosificación o de la formulación farmacéutica para tratar una enfermedad neurodegenerativa o relacionada con dopamina, como la enfermedad de huntington, entre otras.
CL2019000245A1 (es) Moduladores nmda espiro-lactam y métodos de uso de los mismos.
CL2017002939A1 (es) Composiciones farmacéuticas tópicas
CL2020000747A1 (es) Formulaciones de niraparib.
BR112017006957A2 (pt) formulações farmacêuticas para a liberação por via oral de fármacos do tipo de peptídeo ou proteína
CL2019000248A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
PE20170302A1 (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
CO7101246A2 (es) Compuesto de carbamato y preparación y uso de los mismos
CO2019000941A2 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
BR112016025997A8 (pt) compostos para tratamento de doenças e lesões oftalmológicas, uma composição farmacêutica e uma formulação oftálmica
CL2019000247A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
CO2019000944A2 (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos
MX2021003110A (es) Agonistas del receptor x farnesoide y usos de los mismos.
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
BR112015019802A2 (pt) formulações farmacêuticas de nitrito e usos das mesmas
HRP20240812T1 (hr) Oblici doziranja i terapijska primjena l-4-klorokinurenina
MX2019015927A (es) Composiciones para administración de fármacos y métodos de uso de las mismas.
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.
MX384159B (es) Formulaciones y métodos para el suministro vaginal de antiprogestinas.
MX391191B (es) Composiciones de liberación extendida de onapristona y métodos.
MX2021000029A (es) Profarmacos y moduladores de receptores nmda, sales y usos de estos.
BR112018072183A2 (pt) composição farmacêutica, e, método para prevenir uma doença de pele
MX380536B (es) Composicion y metodo para tratar la enfermedad de chagas.
AR116594A1 (es) Tratamiento del temblor esencial usando (r)-2-(4-isopropilfenil)-n-(1-(5-(2,2,2-trifluoroetoxi)piridin-2-il)etil)acetamida

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements